AU2014250937A1 - Sustained release of bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction - Google Patents

Sustained release of bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction Download PDF

Info

Publication number
AU2014250937A1
AU2014250937A1 AU2014250937A AU2014250937A AU2014250937A1 AU 2014250937 A1 AU2014250937 A1 AU 2014250937A1 AU 2014250937 A AU2014250937 A AU 2014250937A AU 2014250937 A AU2014250937 A AU 2014250937A AU 2014250937 A1 AU2014250937 A1 AU 2014250937A1
Authority
AU
Australia
Prior art keywords
bimatoprost
composition
fat
sustained release
reduction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2014250937A
Other languages
English (en)
Inventor
Patrick M. Hughes
Scott M. Whitcup
David F. Woodward
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of AU2014250937A1 publication Critical patent/AU2014250937A1/en
Priority to AU2019203214A priority Critical patent/AU2019203214B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Child & Adolescent Psychology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Materials For Medical Uses (AREA)
AU2014250937A 2013-04-12 2014-04-09 Sustained release of bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction Abandoned AU2014250937A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2019203214A AU2019203214B2 (en) 2013-04-12 2019-05-08 Sustained release of bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361811682P 2013-04-12 2013-04-12
US61/811,682 2013-04-12
PCT/US2014/033558 WO2014169075A1 (en) 2013-04-12 2014-04-09 Sustained release of bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2019203214A Division AU2019203214B2 (en) 2013-04-12 2019-05-08 Sustained release of bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction

Publications (1)

Publication Number Publication Date
AU2014250937A1 true AU2014250937A1 (en) 2015-10-22

Family

ID=51686960

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2014250937A Abandoned AU2014250937A1 (en) 2013-04-12 2014-04-09 Sustained release of bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction
AU2019203214A Ceased AU2019203214B2 (en) 2013-04-12 2019-05-08 Sustained release of bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2019203214A Ceased AU2019203214B2 (en) 2013-04-12 2019-05-08 Sustained release of bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction

Country Status (18)

Country Link
US (2) US20140308354A1 (cg-RX-API-DMAC7.html)
EP (2) EP2983663B1 (cg-RX-API-DMAC7.html)
JP (1) JP2016520561A (cg-RX-API-DMAC7.html)
KR (1) KR20150141972A (cg-RX-API-DMAC7.html)
CN (2) CN110840899A (cg-RX-API-DMAC7.html)
AU (2) AU2014250937A1 (cg-RX-API-DMAC7.html)
BR (1) BR112015025915A8 (cg-RX-API-DMAC7.html)
CA (1) CA2908731A1 (cg-RX-API-DMAC7.html)
CL (1) CL2015003023A1 (cg-RX-API-DMAC7.html)
DK (1) DK2983663T3 (cg-RX-API-DMAC7.html)
ES (1) ES2785382T3 (cg-RX-API-DMAC7.html)
IL (1) IL242006B (cg-RX-API-DMAC7.html)
MX (1) MX381097B (cg-RX-API-DMAC7.html)
MY (1) MY187802A (cg-RX-API-DMAC7.html)
RU (1) RU2015143859A (cg-RX-API-DMAC7.html)
SG (2) SG10201701938PA (cg-RX-API-DMAC7.html)
WO (1) WO2014169075A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201507217B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102159427B1 (ko) * 2015-04-30 2020-09-24 알러간, 인코포레이티드 지방 감소를 위한 미용적 방법 및 치료적 용도
US11452703B2 (en) * 2020-05-21 2022-09-27 Peregrine Ophthalmic PTE LTD. Methods and compositions for reducing adipocyte numbers
JP7879845B2 (ja) * 2020-07-21 2026-06-24 アラーガン、インコーポレイテッド プロスタミドが高充填された眼内インプラント
EP4698184A1 (en) * 2023-04-18 2026-02-25 Welfare Concepts Limited Composition and method for inducing luteolysis

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2218424A (en) * 1931-05-07 1940-10-15 Teleregister Corp Transmitter and code translator
US4525359A (en) * 1982-12-10 1985-06-25 Greenway Frank L Iii Treatment for selective weight control
US6124344A (en) * 1993-12-28 2000-09-26 Allergan Sales, Inc. Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
DE69613693T2 (de) * 1995-05-18 2002-05-16 Allergan Sales, Inc. 2-heteroarylalkenylderivate der cyclopentano-heptan(heptaen)säure als therapeutisches mittel zur behandlung des erhöhten augeninnendruckes
ES2379652T3 (es) 2002-10-23 2012-04-30 Sucampo Ag Compuestos de prostaglandina para el tratamiento de obesidad
CA2508303C (en) * 2002-12-04 2012-10-23 Santen Pharmaceutical Co., Ltd. Drug delivery system using subconjunctival depot
WO2005063205A2 (en) * 2003-12-22 2005-07-14 Aventis Pharmaceuticals Inc. Injectable phosphatidylcholine preparations
US20080038316A1 (en) 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
WO2007111806A2 (en) * 2006-03-23 2007-10-04 Massachusetts Eye And Ear Infirmary Cyclopentane heptanoic acid compounds for reducing body fat
AU2007313077B2 (en) * 2006-10-17 2011-06-02 Neothetics, Inc. Methods, compositions, and formulations for the treatment of thyroid eye disease
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US9095506B2 (en) * 2008-11-17 2015-08-04 Allergan, Inc. Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
US20100247606A1 (en) * 2009-03-25 2010-09-30 Allergan, Inc. Intraocular sustained release drug delivery systems and methods for treating ocular conditions
US20130071349A1 (en) * 2010-03-02 2013-03-21 Allergan, Inc. Biodegradable polymers for lowering intraocular pressure
EP2595604B1 (en) 2010-07-21 2016-03-30 Allergan, Inc. Method of controlling initial drug release of sirna from sustained-release implants
ES2751681T3 (es) * 2013-03-15 2020-04-01 Allergan Inc Implante intraocular que contiene prostamida
KR102159427B1 (ko) 2015-04-30 2020-09-24 알러간, 인코포레이티드 지방 감소를 위한 미용적 방법 및 치료적 용도

Also Published As

Publication number Publication date
MX381097B (es) 2025-03-12
CN110840899A (zh) 2020-02-28
MX2015014320A (es) 2015-12-08
EP3656375A1 (en) 2020-05-27
AU2019203214A1 (en) 2019-05-30
MY187802A (en) 2021-10-26
HK1221406A1 (en) 2017-06-02
KR20150141972A (ko) 2015-12-21
ES2785382T3 (es) 2020-10-06
SG10202109919PA (en) 2021-10-28
RU2015143859A (ru) 2017-05-16
CA2908731A1 (en) 2014-10-16
US10682361B2 (en) 2020-06-16
DK2983663T3 (da) 2020-04-20
CN105101962A (zh) 2015-11-25
US20140308354A1 (en) 2014-10-16
AU2019203214B2 (en) 2020-10-29
JP2016520561A (ja) 2016-07-14
WO2014169075A1 (en) 2014-10-16
RU2015143859A3 (cg-RX-API-DMAC7.html) 2018-03-05
IL242006B (en) 2020-04-30
BR112015025915A2 (pt) 2017-07-25
CL2015003023A1 (es) 2016-06-10
BR112015025915A8 (pt) 2020-01-14
EP2983663A1 (en) 2016-02-17
EP2983663B1 (en) 2020-01-22
ZA201507217B (en) 2017-09-27
NZ712804A (en) 2021-02-26
SG10201701938PA (en) 2017-04-27
US20160339039A1 (en) 2016-11-24

Similar Documents

Publication Publication Date Title
Hatefi et al. Biodegradable injectable in situ forming drug delivery systems
Nguyen et al. Design and translation of injectable biomaterials
AU2019203214B2 (en) Sustained release of bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction
EP1581181B1 (en) Controlled release depot formulations
US20040109893A1 (en) Sustained release dosage forms of anesthetics for pain management
EP2067468A1 (en) Sustained release dosage forms of anesthetics for pain management
JP2005538107A5 (ja) 注入可能な多モードポリマーのデポ組成物及びその使用
US20100285113A1 (en) Enhanced stability of inverse thermal gelling composite hydrogels
NZ574443A (en) Short duration depot formulations
JP2016520561A5 (cg-RX-API-DMAC7.html)
Vora et al. Injectable depot-forming hydrogels for long-acting drug delivery
Ito et al. Application of calcium phosphate as a controlled-release device
HK40031326A (en) Sustained release of bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction
HK40025309A (en) Subtained release of bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction
NZ712804B2 (en) Sustained release of bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction
HK1221406B (en) Sustained release of bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction
EP3986491B1 (en) Crosslinkable hydrogel compositions
CN118697697B (zh) 一种脂质体封装的长效罗哌卡因缓释系统
KR20230022737A (ko) 주사용 사전-제형 및 이를 이용한 도네페질 초기방출 억제형 키트
HK1085387B (en) Controlled release depot formulations

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted